Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB9741 in healthy Caucasian and Japanese participants
NCT06315335Phase 1Completed
- Sponsor
- UCB
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galvokimig (5 cohorts), sponsored by UCB. Primary endpoints: Treatment-Emergent Adverse Events at 8 weeks and Serious Adverse Events at 8 weeks. Started Jul 2024; status: completed.
02
Drugs
galvokimig
Beyond the preview
Go deeper on NCT06315335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315335.